Literature DB >> 2659272

Cholera toxin and its subunits as potential oral adjuvants.

C O Elson.   

Abstract

Cholera toxin has been shown to have adjuvant effects in multiple different systems. The dose, timing and genetic background of the recipient all seem to be important variables. The role of the two subunits in both the immunogenicity and the adjuvanticity of this molecule remain unclear. The mechanisms of the adjuvant effect likely involves effects on regulatory T cells; there is evidence that the adjuvant effect is due at least in part to inhibition of suppressor T cells. When KLH is used as a model antigen, the adjuvanticity of cholera toxin appears to be related to its immunogenicity in that both properties occur mainly in mouse strains that are high responders to cholera toxin. The genetic engineering of chimeric neoantigens consisting of cholera toxin subunits coupled to antigens of interest has been shown to be technically possible and is an attractive future approach for the generation of effective oral vaccines.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2659272     DOI: 10.1007/978-3-642-74529-4_3

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  31 in total

1.  Cholera toxin B-subunit gene enhances mucosal immunoglobulin A, Th1-type, and CD8+ cytotoxic responses when coadministered intradermally with a DNA vaccine.

Authors:  Alba E Sanchez; Guillermo Aquino; Pedro Ostoa-Saloma; Juan P Laclette; Leticia Rocha-Zavaleta
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

2.  Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens.

Authors:  Sabena Uddowla; Lucy C Freytag; John D Clements
Journal:  Vaccine       Date:  2007-10-02       Impact factor: 3.641

3.  Expression of cholera toxin B subunit in transgenic rice endosperm.

Authors:  Maria Oszvald; Tae-Jin Kang; Sandor Tomoskozi; Barnabas Jenes; Tae-Geum Kim; Youn-Soo Cha; Laszlo Tamas; Moon-Sik Yang
Journal:  Mol Biotechnol       Date:  2008-07-10       Impact factor: 2.695

4.  Distribution, persistence, and recall of serum and salivary antibody responses to peroral immunization with protein antigen I/II of Streptococcus mutans coupled to the cholera toxin B subunit.

Authors:  M W Russell; H Y Wu
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

5.  Oral immunization with the saliva-binding region of Streptococcus mutans AgI/II genetically coupled to the cholera toxin B subunit elicits T-helper-cell responses in gut-associated lymphoid tissues.

Authors:  N Toida; G Hajishengallis; H Y Wu; M W Russell
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

Review 6.  Recent progress in mucosal vaccine development: potential and limitations.

Authors:  Nils Lycke
Journal:  Nat Rev Immunol       Date:  2012-07-25       Impact factor: 53.106

7.  Cholera toxin subunit B inhibits IL-12 and IFN-{gamma} production and signaling in experimental colitis and Crohn's disease.

Authors:  E M Coccia; M E Remoli; C Di Giacinto; B Del Zotto; E Giacomini; G Monteleone; M Boirivant
Journal:  Gut       Date:  2005-08-16       Impact factor: 23.059

Review 8.  Host-pathogen interaction in amebiasis and progress in vaccine development.

Authors:  C D Huston; W A Petri
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-09       Impact factor: 3.267

9.  Oral immunization with the dodecapeptide repeat of the serine-rich Entamoeba histolytica protein (SREHP) fused to the cholera toxin B subunit induces a mucosal and systemic anti-SREHP antibody response.

Authors:  T Zhang; E Li; S L Stanley
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

Review 10.  Vaccine adjuvants: current challenges and future approaches.

Authors:  Jennifer H Wilson-Welder; Maria P Torres; Matt J Kipper; Surya K Mallapragada; Michael J Wannemuehler; Balaji Narasimhan
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.